Sandoz announces global biosimilars collaboration with Biocon

Amy Schofield 18 January 2018

Sandoz has announced a global partnership with Biocon to develop, manufacture and commercialise multiple biosimilars in immunology and oncology for patients worldwide.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally.

Worldwide commercialisation responsibilities will be divided and each company's strengths will be leveraged within specific geographies. Sandoz will lead commercialisation in North America and the EU, while Biocon will lead commercialisation in Rest of the World.

Richard Francis, CEO, Sandoz, said: "Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.